Skip to Content

Erythromycin eent

Class: Antibacterials
CAS Number: 114-07-08
Brands: Romycin

Medically reviewed on July 3, 2017

Introduction

Antibacterial; macrolide antibiotic.a b

Uses for Erythromycin

Bacterial OphthalmicInfections

Treatment of superficial infections of the eye involving the conjunctiva and/or cornea caused by susceptible organisms.a b

Concomitant systemic anti-infective therapy may be required, except for very superficial infections.a b

Chlamydial Ophthalmic Infections

Has been used as an adjunct to oral anti-infective therapy in the treatment of trachoma and inclusion conjunctivitis;118 122 127 128 129 130 131 133 134 however, oral azithromycin is the drug of choice for treatment of ocular trachoma caused by Chlamydia trachomatis.138

Efficacy of topical prophylaxis for the prevention of chlamydial neonatal conjunctivitis has not been established.101 102 103 104 105 106 107 109 114 116 117 118 135 136

Prophylaxis of Gonococcal Ophthalmia Neonatorum

Prophylaxis of gonococcal ophthalmia neonatorum.a b CDC and AAP recommend topical prophylaxis in all neonates as soon as possible after birth; prophylaxis required by law in most states.117 118

One of several topical agents recommended by CDC and AAP;117 118 some state or local public health regulations may still require prophylactic use of silver nitrate rather than other anti-infectives.a

Efficacy not established in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae.a b

Infants born to women with untreated gonorrhea should receive systemic prophylaxis (e.g., ceftriaxone) in addition to topical prophylaxis.117 118 If gonococcal ophthalmia is diagnosed, systemic therapy (e.g., ceftriaxone) is necessary.116 117

Erythromycin Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the eye as an ointment.a b

Avoid contamination of the tip of the ointment tube.a b

Following placement of ointment in neonate’s lower conjunctival sacs, massage gently to spread ointment; wipe away excess ointment with sterile cotton after 1 minute.a Do not flush ointment from the eye following application.b Use a new tube or single-use container of ointment for each neonate.b

Dosage

Pediatric Patients

Bacterial Ophthalmic Infections
Ophthalmic

Apply 1-cm ribbon of 0.5% ointment to the infected eye(s) up to 6 times daily.a b

Chlamydial Ophthalmic Infections
Trachoma
Ophthalmic

Apply a small amount of 0.5% ointment to each eye twice daily for 2 months or twice daily for the first 5 days of each month for 6 months.118

Prophylaxis of Gonococcal Ophthalmia Neonatorum
Ophthalmic

Place a 1-cm ribbon of 0.5% ointment in the lower conjunctival sacs of both eyes shortly after birth.a b

Adults

Bacterial Ophthalmic Infections
Ophthalmic

Apply a 1-cm ribbon of 0.5% ointment to the infected eye(s) up to 6 times daily.a b

Chlamydial Infections
Trachoma
Ophthalmic

Apply a small amount of 0.5% ointment to each eye twice daily for 2 months or twice daily for the first 5 days of each month for 6 months.118

Cautions for Erythromycin

Contraindications

  • Hypersensitivity to erythromycin or any ingredient in the formulation.a b

Warnings/Precautions

Sensitivity Reactions

Sensitivity

Possible sensitivity reactions.a b

General Precautions

Superinfection

Possible emergence and overgrowth of nonsusceptible organisms, including fungi.a b

Discontinue drug and institute appropriate therapy if superinfection occurs.a b

Specific Populations

Pregnancy

Category B.b

Lactation

Caution advised in nursing women.b

Pediatric Use

See Uses.

Common Adverse Effects

Minor ocular irritation, redness, hypersensitivity.a b

Erythromycin Pharmacokinetics

Absorption

Extent

Topical application probably does not produce significant antibacterial concentrations in deep layers of the cornea or in the aqueous humor.a

Not known whether erythromycin is absorbed to any substantial extent from mucous membranes.a

Stability

Storage

Ophthalmic

Ointment

15–30°C.b

Actions and Spectrum

  • Usually bacteriostatic; may be bactericidal in high concentrations or against highly susceptible organisms.a

  • Inhibits protein synthesis in susceptible organisms by binding to 50S ribosomal subunits.a b

  • Most effective against gram-positive cocci (staphylococci and streptococci) and gram-positive bacilli; also effective against some gram-negative cocci (Neisseria species) and some gram-negative bacilli (including some strains of Haemophilus influenzae and Moraxella lacunata).a b Also active against Chlamydia.a b

Advice to Patients

  • Importance of not contaminating the tip of the ointment tube.a b

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.a b

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.

  • Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Erythromycin

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Ophthalmic

Ointment

0.5%*

Erythromycin Ophthalmic Ointment

Akorn, Bausch & Lomb, Fougera

Romycin

OCuSOFT

AHFS DI Essentials. © Copyright 2018, Selected Revisions July 1, 2006. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

101. Anon. Neonatal gonococcal ophthalmia—California. MMWR Morb Mortal Wkly Rep. 1983; 32:518-9. http://www.ncbi.nlm.nih.gov/pubmed/6412066?dopt=AbstractPlus

102. Zola EM. Evaluation of drugs used in the prophylaxis of neonatal conjunctivitis. Drug Intell Clin Pharm. 1984; 18:692-6. http://www.ncbi.nlm.nih.gov/pubmed/6383753?dopt=AbstractPlus

103. Hammerschlag MR, Chandler JW, Alexander ER et al. Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection. JAMA. 1980; 244:2291-3. http://www.ncbi.nlm.nih.gov/pubmed/7431552?dopt=AbstractPlus

104. Rettig PJ, Patamasucon P, Siegel JD. Postnatal prophylaxis of chlamydial conjunctivitis. JAMA. 1981; 246: 2321-2. http://www.ncbi.nlm.nih.gov/pubmed/7299949?dopt=AbstractPlus

105. Anon. Antibiotic-resistant strains of Neisseria gonorrhoeae. Policy guidelines for detection, management, and control. MMWR Morb Mortal Wkly Rep. 1987; 36(Suppl 5):15-6S.

106. Dillon HC Jr. Prevention of gonococcal ophthalmia neonatorum. N Engl J Med. 1986; 315:1414-5. http://www.ncbi.nlm.nih.gov/pubmed/3773967?dopt=AbstractPlus

107. Sandstrom I. Ophthalmia neonatorum with special reference to Chlamydia trachomatis: diagnosis and treatment. Acta Paediatr Scand. 1986; 330:3-27.

109. Hammerschlag MR. Neonatal ocular prophylaxis. Pediatr Infect Dis J. 1988; 7:81-2. http://www.ncbi.nlm.nih.gov/pubmed/3344174?dopt=AbstractPlus

114. Fransen L, Klauss V. Neonatal ophthalmia in the developing world: epidemiology, etiology, management and control. Int Ophthalmol. 1988; 11:189-96. http://www.ncbi.nlm.nih.gov/pubmed/3047073?dopt=AbstractPlus

116. Bell TA, Sandstrom KI, Gravett MG et al. Comparison of ophthalmic silver nitrate solution and erythromycin ointment for prevention of natally acquired Chlamydia trachomatis. Sex Transm Dis. 1987; 14:195-200. http://www.ncbi.nlm.nih.gov/pubmed/3438783?dopt=AbstractPlus

117. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep. 2002; 51(No. RR-6):1-78. http://www.cdc.gov/mmwr/PDF/rr/rr5106.pdf

118. Committee on Infectious Diseases, American Academy of Pediatrics. Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:208-12,735,741.

120. Benson JW, Davidson DC. Neonatal chlamydia conjunctivitis. Br Med J. 1978; 2:961. http://www.ncbi.nlm.nih.gov/pubmed/709165?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1608074&blobtype=pdf

121. Ridgway GL, Oriel JD. Treatment of neonatal inclusion blenorrhea. N Engl J Med. 1977; 297:512. http://www.ncbi.nlm.nih.gov/pubmed/887138?dopt=AbstractPlus

122. Rowe DS, Aicardi EZ, Dawson CR et al. Purulent ocular discharge in neonates: significance of chlamydia trachomatis. Pediatrics. 1979; 63:628-32. http://www.ncbi.nlm.nih.gov/pubmed/440875?dopt=AbstractPlus

123. Schachter J. Chlamydial infections (third of three parts). N Engl J Med. 1978; 298:540-9. http://www.ncbi.nlm.nih.gov/pubmed/342952?dopt=AbstractPlus

124. Moore RA, Schmitt BD. Conjunctivitis in children. Clin Ped. 1979; 18:26-30.

125. Lorian V. Antibiotics in laboratory medicine. Baltimore, MD: Williams and Wilkins; 1980:419, 471.

126. Ridgway GL. Chlamydial infections in pediatrics. Arch Dis Child. 1978; 53:447-8. http://www.ncbi.nlm.nih.gov/pubmed/356747?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1544965&blobtype=pdf

127. Roy FH. Trachoma. Ann Ophthalmol. 1974; 6:1167-71. http://www.ncbi.nlm.nih.gov/pubmed/4429322?dopt=AbstractPlus

128. Vastine DW, Dawson CR, Daghfous T et al. Severe endemic trachoma in Tunisia: I. Effect of topical chemotherapy on conjunctivitis and ocular bacteria. Br J Ophthalmol. 1974; 58:833-42. http://www.ncbi.nlm.nih.gov/pubmed/4451650?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1215039&blobtype=pdf

129. Maichuk YF. Some aspects of rational trachoma therapy. Am J Ophthalmol. 1972; 74:684-703.

130. Dawson CR, Daghfous T, Whitcher J et al. Intermittent trachoma chemotherapy: a controlled trial of topical tetracycline or erythromycin. Bull World Health Organ. 1981; 59:91-7. http://www.ncbi.nlm.nih.gov/pubmed/7020973?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2396018&blobtype=pdf

131. Dawson CR, Daghfous T, Messadi M et al. Severe endemic trachoma in Tunisia. II. A controlled therapy trial of topically applied chlortetracycline and erythromycin. Arch Ophthalmol. 1974; 92:198-203. http://www.ncbi.nlm.nih.gov/pubmed/4137188?dopt=AbstractPlus

132. Dawson C. Therapy of diseases caused by Chlamydia organisms. Int Ophthalmol Clin. 1973; 13:93-101. http://www.ncbi.nlm.nih.gov/pubmed/4593599?dopt=AbstractPlus

133. Whitcher JP, Dawson CR, Messadi M et al. Severe endemic trachoma in Tunisia: changes in ocular bacterial pathogens in children treated by the intermittent antibiotic regimen. Rev Int Trach. 1974; 51:49-58. http://www.ncbi.nlm.nih.gov/pubmed/4157128?dopt=AbstractPlus

134. Dawson CR, Schachter J. Strategies for treatment and control of blinding trachoma: cost-effectiveness of topical or systemic antibiotics. Rev Infect Dis. 1985; 7:768-73. http://www.ncbi.nlm.nih.gov/pubmed/4070912?dopt=AbstractPlus

135. Anon. Drugs for sexually transmitted diseases. Med Lett Drugs Ther. 1999; 41:85-90.

136. Hammerschlag MR, Cummings C, Roblin PM et al. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. N Engl J Med. 1989; 320:769-72. http://www.ncbi.nlm.nih.gov/pubmed/2922026?dopt=AbstractPlus

137. Thylefors B. Azithromycin. A new opportunity for control of trachoma. WHO Drug Information. 1996; 10:132-3.

138. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 2001; 43:69-78. http://www.ncbi.nlm.nih.gov/pubmed/11518876?dopt=AbstractPlus

a. AHFS Drug Information 2003. McEvoy, GK, ed. Erythromycin (ophthalmic ointment). Bethesda, MD: American Society of Health-System Pharmacists; 2598-9.

b. Dista (Eli Lilly). Ilotycin (erythromycin) ophthalmic ointment prescribing information. In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company Inc; 2001:1123-4.

Hide